MCID: CTR002
MIFTS: 60

Cataract

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Cataract

Summaries for Cataract

KEGG : 36 Cataracts can be defined as any opacity of the crystalline lens, often associated with breakdown of the lens microarchitecture, possibly including vacuole formation and disarray of lens cells, which can cause large fluctuations in density resulting in light scattering. In addition, light scattering and opacity will occur if there is a significant amount of high molecular weight protein aggregates. Cataracts can be classified by the age at onset: a congenital or infantile cataract presents within the first year of life; a juvenile cataract presents within the first decade of life; a presenile cataract presents before the age of about 45 years, and senile or age-related cataract after that. Congenital cataracts are a major cause of induced blindness in children, and inherited cataracts are the major cause of congenital cataracts. Inherited congenital cataracts have been associated with mutations in specific genes, including those of crystallins, gap junction proteins, membrane transport and channel proteins, the cytoskeleton, and growth and transcription factors. Inherited congenital cataracts may be inherited as autosomal dominant (most frequent), autosomal recessive, or X-linked traits.

MalaCards based summary : Cataract, also known as cataracts, is related to cataract 1, multiple types and cataract 9, multiple types. An important gene associated with Cataract is LIM2 (Lens Intrinsic Membrane Protein 2), and among its related pathways/superpathways is Protein processing in endoplasmic reticulum. The drugs Dipivefrin and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include Eye, endothelial and bone marrow, and related phenotype is vision/eye.

Disease Ontology : 12 A lens disease characterized by clouding of the lens inside the eye which leads to a decrease in vision.

MedlinePlus : 42 A cataract is a clouding of the lens in your eye. It affects your vision. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery. A cataract can occur in either or both eyes. It cannot spread from one eye to the other. Common symptoms are Blurry vision Colors that seem faded Glare - headlights, lamps or sunlight may seem too bright. You may also see a halo around lights. Not being able to see well at night Double vision Frequent prescription changes in your eye wear Cataracts usually develop slowly. New glasses, brighter lighting, anti-glare sunglasses or magnifying lenses can help at first. Surgery is also an option. It involves removing the cloudy lens and replacing it with an artificial lens. Wearing sunglasses and a hat with a brim to block ultraviolet sunlight may help to delay cataracts. NIH: National Eye Institute

PubMed Health : 62 About cataracts: A cataract is an eye condition in which the lens of the eye becomes cloudy. This causes vision to worsen, making it especially difficult to see fine details clearly. Some people’s vision is only slightly affected, whereas others might lose their eyesight very quickly. How it progresses will depend on things like the exact type of cataract. The word “cataract” comes from the Greek word for “waterfall” because in the past it was believed that the blurring was caused by a fluid in the eye. Cataracts mostly affect people over 50, and the risk increases with age: About 20 out of 100 people between the ages of 65 and 74 have a cataract. And more than 50 out of 100 people over the age of 74 are affected. Cataracts are the main cause of blindness in developing countries. The number of people who go blind from cataracts is considerably lower in industrialized countries due to the availability of effective surgery. Cataract surgery involves removing the cloudy eye lens and replacing it with an artificial lens. It is one of the most common surgical procedures performed in Germany, where about 800,000 people have cataract surgery every year.

Wikipedia : 74 A cataract is a cloudy area in the lens of the eye that leads to a decrease in vision. Cataracts often... more...

Related Diseases for Cataract

Diseases in the Cataract family:

Cataract 32, Multiple Types Cataract 7
Cataract 8, Multiple Types Cataract 4, Multiple Types
Cataract 29 Cataract 42
Cataract 20, Multiple Types Cataract 1, Multiple Types
Cataract 30, Multiple Types Cataract 41
Cataract 6, Multiple Types Cataract 5, Multiple Types
Cataract 40 Cataract 10, Multiple Types
Cataract 24 Cataract 3, Multiple Types
Cataract 14, Multiple Types Cataract 9, Multiple Types
Cataract 2, Multiple Types Cataract 31, Multiple Types
Cataract 25 Cataract 26, Multiple Types
Cataract 27 Cataract 28
Cataract 35 Cataract 22, Multiple Types
Cataract 18 Cataract 21, Multiple Types
Cataract 23, Multiple Types Cataract 11, Multiple Types
Cataract 33, Multiple Types Cataract 17, Multiple Types
Cataract 12, Multiple Types Cataract 47
Cataract 34, Multiple Types Cataract 16, Multiple Types
Cataract 36 Cataract 37
Cataract 38 Cataract 39, Multiple Types
Cataract 15, Multiple Types Cataract 19, Multiple Types
Cataract 43 Cataract 44
Cataract 45 Cataract 48
Cataract 30 Cataract 33
Cataract Congenital Autosomal Dominant Cataract, Total Congenital

Diseases related to Cataract via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1669)
# Related Disease Score Top Affiliating Genes
1 cataract 1, multiple types 33.5 GJA8 GJA3 CRYAA
2 cataract 9, multiple types 33.3 GJA8 CRYAA
3 cataract 6, multiple types 33.3 CRYBA1 CRYAA
4 cataract 11, multiple types 33.3 CRYBA1 CRYAA
5 cataract microcornea syndrome 33.3 GJA8 CRYGD CRYAA
6 cataract 14, multiple types 33.2 GJA8 GJA3
7 senile cataract 33.1 WRN CRYGS CRYAA
8 cataract 30, multiple types 33.1 GJA8 GJA3 CRYGD
9 cataract 32, multiple types 33.1 CRYBA1 CRYAA
10 cataract 44 33.1 LIM2 GJA8 CRYAA
11 cataract 16, multiple types 33.1 CRYBA1 CRYAA
12 cataract 31, multiple types 33.1 CRYBA1 CRYAA
13 nance-horan syndrome 33.1 GJA8 CRYGD CRYAA
14 cataract 24 33.1 CTAA2 CRYAA
15 aniridia 1 33.1 GJA8 CRYGS CRYGD CRYBA1 CRYAA
16 posterior polar cataract 33.1 GJA3 CRYGD CRYBA1 CRYAA
17 immature cataract 33.1 GJA8 GJA3 CRYAA
18 mature cataract 33.1 GJA8 CRYGS CRYGD CRYAA
19 cataract 28 33.0 CTRCT28 CRYAA
20 cataract 29 32.9 CTRCT29 CRYGD
21 cerulean cataract 32.9 CTRCT37 CRYGD
22 morgagni cataract 32.8 CRYGS CRYAA
23 galactosemia ii 32.8 LIM2 CRYGS CRYAA
24 diabetic cataract 32.7 CRYGS CRYAA
25 nuclear senile cataract 32.7 CRYGS CRYGD
26 amblyopia 32.7 GJA8 GJA3 CRYGS CRYGD CRYAA
27 early-onset non-syndromic cataract 32.5 LIM2 GJA3 CRYGS CRYBA1
28 early-onset sutural cataract 32.4 GJA8 CRYGS CRYBA1
29 early-onset nuclear cataract 32.4 GJA8 GJA3 CRYGD CRYBA1 CRYAA
30 early-onset lamellar cataract 32.2 CRYGS CRYGD CRYBA1 CRYAA
31 early-onset posterior polar cataract 32.2 GJA3 CRYBA1
32 presbyopia 31.7 LIM2 CRYGS CRYGD CRYAA
33 macular retinal edema 31.5 RHO CRYAA
34 lens disease 31.1 WRN SIL1 RHO GJA8 GJA3 CRYGS
35 leukocoria 30.9 CRYBA1 CRYAA
36 scleral staphyloma 30.5 CRYBA1 CRYAA
37 sclerocornea 30.5 GJA8 CRYAA
38 disuse amblyopia 30.2 CRYGS CRYAA
39 hereditary retinal dystrophy 29.8 RHO CRYAA
40 vitreous disease 29.7 RHO CRYAA
41 cataract 4, multiple types 11.6
42 hyperferritinemia with or without cataract 11.6
43 cataract 21, multiple types 11.6
44 cataract 3, multiple types 11.6
45 optic atrophy 3, autosomal dominant 11.6
46 leukodystrophy, hypomyelinating, 5 11.6
47 cataract 2, multiple types 11.6
48 cataract 40 11.5
49 cataract 47 11.5
50 cataract 22, multiple types 11.5

Graphical network of the top 20 diseases related to Cataract:



Diseases related to Cataract

Symptoms & Phenotypes for Cataract

MGI Mouse Phenotypes related to Cataract:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.28 CRYBA1 CRYGD CRYGS GJA3 GJA8 IARS2

Drugs & Therapeutics for Cataract

PubMed Health treatment related to Cataract: 62

Some people can compensate for the vision loss, temporarily or even in the longer term, by wearing glasses or contact lenses . There are no medications for the treatment of cataracts . The only effective treatment is surgery . Cataract surgery involves removing the cloudy lens and replacing it with a new, artificial lens. The lens capsule – an elastic membrane surrounding the lens of the eye – is left in the eye during surgery. Only the inner core and the outer cortex of the lens are broken up into small pieces using ultrasound. The pieces are then sucked out of the eye through a small cut. This procedure, called phacoemulsification , is the standard technique in Germany and some other countries. Once the lens has been removed, an artificial lens is implanted into the lens capsule. Whether and when surgery is an appropriate treatment option is very much a personal decision. The extent to which vision loss is affecting someone’s life will play a very important role. Another factor to consider is the presence of other (eye ) conditions, which could affect the outcome of cataract surgery .

Drugs for Cataract (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 312)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dipivefrin Approved Phase 4 52365-63-6 3105
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
3
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
4
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
5
Travoprost Approved Phase 4 157283-68-6 5282226
6
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
7
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
10
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
13
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
14
Bromfenac Approved Phase 4 91714-94-2 60726
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
16 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
17
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
18
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
21
Vancomycin Approved Phase 4 1404-90-6 441141 14969
22
Dinoprostone Approved Phase 4 363-24-6 5280360
23
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
24
Besifloxacin Approved Phase 4 141388-76-3
25 Orange Approved Phase 4
26
Ofloxacin Approved Phase 4 82419-36-1 4583
27
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
28
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
29
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
30
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
31
Azithromycin Approved Phase 4 83905-01-5 55185 447043
32
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
33
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
34
Homatropine Approved Phase 4 87-00-3
35
Dalteparin Approved Phase 4 9005-49-6
36
Enoxaparin Approved Phase 4 9005-49-6 772
37
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
38
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
39
Bevacizumab Approved, Investigational Phase 4 216974-75-3
40
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
41
Ranibizumab Approved Phase 4 347396-82-1 459903
42
Lifitegrast Approved Phase 4 1025967-78-5
43
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
44
tannic acid Approved Phase 4 1401-55-4
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
46
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
47
Difluprednate Approved Phase 4 23674-86-4 443936
48
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
49
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
50
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529

Interventional clinical trials:

(show top 50) (show all 1192)
# Name Status NCT ID Phase Drugs
1 Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies Unknown status NCT00865540 Phase 4 prednisolone acetate 1%;ketorolac tromethamine 0.4%;nepafenac 0.1%;methylcellulose 0.5%
2 A Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent Unknown status NCT03255785 Phase 4
3 Relevance of Eye Dominance in the Selection of Patients Suitable for Treatment With Monovision After Cataract Surgery Unknown status NCT01382641 Phase 4
4 Clinical Evaluation of Toric Intraocular Lens Made by Aurolab Unknown status NCT01396616 Phase 4
5 A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin Unknown status NCT02873806 Phase 4 Topical travoprost;Tobramycin;Dexamethasone
6 The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery Unknown status NCT02127853 Phase 4 gabapentin;placebo
7 Topical 0,09% Bromfenac for Intraoperative Miosis and Pain Reduction in Femtosecond Laser-assisted Cataract Surgery Unknown status NCT03831984 Phase 4 0,09% Bromfenac;0,1% sodium hyaluronate
8 A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery Unknown status NCT02843594 Phase 4
9 AMO's Tecnis™ Multifocal Intraocular Lenses (Tecnis MF), Alcon's ReStor Multifocal IOL Unknown status NCT01278420 Phase 4
10 Efficacy of Subtenon Anesthesia With Olive Tipped Cannula: a Randomized Controlled Trial Unknown status NCT01019018 Phase 4
11 Visual Performance Following Implantation of a Hydrophobic Aspheric Monofocal Intraocular Lens Unknown status NCT03819582 Phase 4
12 Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia. Unknown status NCT03638726 Phase 4 Atropine sulfate and epinephrine;Topical cyclopentolate and phenylephrine
13 A Randomised Intra-patient Comparison of Closed Loop and Plate Haptic Toric, Aspheric, Aberration Neutral, Hydrophilic Acrylic Intraocular Lenses in Patients With Bilateral Astigmatism Unknown status NCT02264457 Phase 4
14 Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens Unknown status NCT02378636 Phase 4
15 Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification Unknown status NCT01193504 Phase 4 Pred Forte;Lotemax
16 Combined Phacoemulsification and Glaucoma Implant Surgery Versus Combined Phacoemulsification and Trabeculectomy: A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
17 Effect of Posterior Corneal Toricity on Refractive Outcome of Pseudophakia Unknown status NCT01554761 Phase 4
18 Intraidivisual Comparison of Functional Vision Provided by AMO Tecnis Z9000 and ALcon SA60AT Acrysof Posterior Chamber Intraocular Lenses Completed NCT00459303 Phase 4
19 Protein Profile of Immunoregulatory Factors in Diabetic Cataract Completed NCT01832311 Phase 4 Ketorolac
20 Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract Completed NCT00786370 Phase 4 dexmedetomidine;Propofol;Dexemedetomidine
21 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
22 Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL Completed NCT02770924 Phase 4
23 ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL) Completed NCT00684138 Phase 4
24 Mini-flared Kelman Tip and Reverse Tip With Torsional Phaco: Prospective Randomized Comparative Study Completed NCT02089698 Phase 4
25 Comparison of Acular LS With Lotemax to Prevent Anterior Segment Inflammation After Phacoemulsification and Intraocular Lens Implantation Completed NCT00366691 Phase 4 Acular LS;Lotemax
26 DisCoVisc Versus Competitor Completed NCT00712244 Phase 4
27 Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery Completed NCT00904904 Phase 4 Indomethacin ophthalmic solution;Ketorolac Ophthalmic Solution
28 A Multi-centre, Multi-surgeon, Randomized, Controlled, Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Impact of Cataract Grade on the Efficacy and Safety of Femtosecond-laser Assisted Lens Fragmentation Procedure Completed NCT01971177 Phase 4
29 To Compare the Ability of DiscoVisc® Ophthalmic Viscosurgical Device (OVD) to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery. Completed NCT00763360 Phase 4 Healon;Amvisc Plus
30 A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs Completed NCT00963560 Phase 4
31 Influence of Light-filters in IOLs on Color Perception and Contrast Acuity. A Randomized, Double-masked Study With Intraindividual Comparison. Completed NCT00612729 Phase 4
32 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms Completed NCT02028754 Phase 4 Sodium Carboxymethylcellulose;Levofloxacin;Prednisolone
33 Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial Completed NCT01279031 Phase 4
34 Phase IV Study: A Prospective Two-Site Study to Evaluate the Safety and Tolerance of Besivance Versus Vigamox Prophylactically Pre and Post Operatively in Subjects Undergoing Routine Cataract Surgery Completed NCT01455233 Phase 4 besivance;vigamox
35 Visual Function After Bilateral Implantation of AcrySof® Toric Completed NCT00758550 Phase 4
36 Size Progression of Non-Exudative Age-Related Macular Degeneration After Cataract Surgery Completed NCT01165801 Phase 4
37 A Randomized, Subject-masked Comparison of Visual Function After Bilateral Implantation of Presbyopia-correcting IOLs Completed NCT01166971 Phase 4
38 Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects Completed NCT02006693 Phase 4
39 Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism Completed NCT01763151 Phase 4
40 Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery Completed NCT01310127 Phase 4 Bromfenac;Nepafenac
41 Bromfenac 0.09% Versus Dexamethasone 0.1% Ophthalmic Solutions to Reduce Inflammation After Cataract Surgery Completed NCT03317847 Phase 4 Bromfenac 0.09 % Ophthalmic Solution;Dexamethasone 0.1% ophthalmic suspension
42 Intraoperative Floppy Iris Syndrome Completed NCT00711347 Phase 4
43 Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery Completed NCT00924729 Phase 4 Moxifloxacin 0.5% ophthalmic solution;Besifloxacin 0.6% ophthalmic suspension
44 Monocular Study to Evaluate the Safety and Effectiveness of the Akreos™ Toric IOL When Used to Correct Primary Aphakia With the Reduction of Astigmatism Completed NCT00825513 Phase 4
45 Clinical Evaluation of a New Aspheric Intraocular Lens. A Prospective, Multi-Center, Comparative Study. Completed NCT00786565 Phase 4
46 Effectiveness of Liposomial Ozonized-Oil on Ocular Microbial Flora Before Cataract Surgery Completed NCT04087733 Phase 4 OZODROP
47 A Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery Completed NCT02023437 Phase 4
48 Co-Axial Micro-incision Cataract Surgery(C-MICS) Versus Standard Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement System Completed NCT01261975 Phase 4
49 A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery Completed NCT01769313 Phase 4
50 A Randomised Trial of Torsional Ultrasound Versus Longitudinal Ultrasound During Phacoemulsification of Age-related Cataracts: Comparison of Intra-operative Performance and Impact on Post-operative Endothelium Integrity Completed NCT01010490 Phase 4

Search NIH Clinical Center for Cataract

Genetic Tests for Cataract

Genetic tests related to Cataract:

# Genetic test Affiliating Genes
1 Cataract (disease) 29

Anatomical Context for Cataract

MalaCards organs/tissues related to Cataract:

40
Eye, Endothelial, Bone Marrow, Retina, Cortex, Breast, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cataract:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Lens Affected by disease

Publications for Cataract

Articles related to Cataract:

(show top 50) (show all 38390)
# Title Authors PMID Year
1
Efficacy and safety of sodium bromfenac eye drops in the treatment of postoperative inflammation in cataract surgery: A protocol for systematic review and meta-analysis. 42 61
33285687 2020
2
Clinical efficacy of phacoemulsification combined intraocular lens implantation for treatment of high myopia with cataract: A protocol of systematic review. 61 42
33285698 2020
3
Limbus-centered marking technique-assisted continuous circular capsulorhexis. 42
33466181 2021
4
Cerebrotendinous xanthomatosis (CTX): an association of pulverulent cataracts and pseudo-dominant developmental delay in a family with a splice site mutation in CYP27A1--a case report. 61 54
20450308 2010
5
In vivo lens deficiency of the R49C alphaA-crystallin mutant. 61 54
20188090 2010
6
A novel human CRYGD mutation in a juvenile autosomal dominant cataract. 61 54
20508808 2010
7
Oxidative stress markers in patients with primary open-angle glaucoma. 54 61
20373896 2010
8
Hyperferritinaemia-cataract syndrome: worldwide mutations and phenotype of an increasingly diagnosed genetic disorder. 61 54
20511138 2010
9
A novel mutation in the major intrinsic protein (MIP) associated with autosomal dominant congenital cataracts in a Chinese family. 54 61
20361015 2010
10
Later retinal degeneration following childhood surgical aphakia in a family with recessive CRYAB mutation (p.R56W). 61 54
20141356 2010
11
HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1. 54 61
20502647 2010
12
[Progress in pathogenic genes and their functions of congenital cataract]. 54 61
20450675 2010
13
Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA. 54 61
19967157 2009
14
A novel GJA8 mutation (p.I31T) causing autosomal dominant congenital cataract in a Chinese family. 54 61
20019893 2009
15
[Hereditary hyperferritinemia cataract syndrome--the first family in Germany]. 61 54
19994473 2009
16
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and senile cataract in a Sardinian male population, Italy. 54 61
19995205 2009
17
[Mutation analysis of the PAX6 gene in a family with congenital aniridia and cataract]. 61 54
19806578 2009
18
Synergistic effects of metal ion and the pre-senile cataract-causing G98R alphaA-crystallin: self-aggregation propensities and chaperone activity. 61 54
19862354 2009
19
A novel mutation (F71L) in alphaA-crystallin with defective chaperone-like function associated with age-related cataract. 61 54
19595763 2009
20
Mutations in MYH9 exons 1, 16, 26, and 30 are infrequently found in Japanese patients with nonsyndromic deafness. 54 61
19645626 2009
21
Effects of alpha-crystallin on lens cell function and cataract pathology. 54 61
19860667 2009
22
Age-related cataracts and Prdx6: correlation between severity of lens opacity, age and the level of Prdx 6 expression. 61 54
19429582 2009
23
A novel gammaD-crystallin mutation causes mild changes in protein properties but leads to congenital coralliform cataract. 61 54
19668596 2009
24
EPHA2 is associated with age-related cortical cataract in mice and humans. 54 61
19649315 2009
25
Antioxidant status modifications by topical administration of dorzolamide in primary open-angle glaucoma. 54 61
19551670 2009
26
Founder heterozygous P23T CRYGD mutation associated with cerulean (and coralliform) cataract in 2 Saudi families. 61 54
19633732 2009
27
Bilateral cataract in a subject carrying a C to A transition in the L ferritin promoter region. 54 61
19254706 2009
28
Aquaporins: translating bench research to human disease. 61 54
19448080 2009
29
An alphaA-crystallin gene mutation, Arg12Cys, causing inherited cataract-microcornea exhibits an altered heat-shock response. 61 54
19503744 2009
30
Initiation codon mutation in betaB1-crystallin (CRYBB1) associated with autosomal recessive nuclear pulverulent cataract. 54 61
19461930 2009
31
Identification of a novel CRYAB mutation associated with autosomal recessive juvenile cataract in a Saudi family. 54 61
19461931 2009
32
Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. 54 61
19437594 2009
33
Deletion of mouse MsrA results in HBO-induced cataract: MsrA repairs mitochondrial cytochrome c. 61 54
19461988 2009
34
Aquaporin water channels in mammals. 61 54
19085041 2009
35
NMR study of the cataract-linked P23T mutant of human gammaD-crystallin shows minor changes in hydrophobic patches that reflect its retrograde solubility. 54 61
19275895 2009
36
Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. 61 54
18588875 2009
37
11p Microdeletion including WT1 but not PAX6, presenting with cataract, mental retardation, genital abnormalities and seizures: a case report. 61 54
19222835 2009
38
Removal of Hsf4 leads to cataract development in mice through down-regulation of gamma S-crystallin and Bfsp expression. 61 54
19224648 2009
39
Genetics of crystallins: cataract and beyond. 61 54
19007775 2009
40
Novel mutation in the gamma-S crystallin gene causing autosomal dominant cataract. 54 61
19262743 2009
41
Oxidative stress markers in aqueous humor of patients with senile cataracts. 61 54
19172468 2009
42
Structural function of MIP/aquaporin 0 in the eye lens; genetic defects lead to congenital inherited cataracts. 61 54
19096783 2009
43
A new locus for congenital cataract, microcornea, microphthalmia, and atypical iris coloboma maps to chromosome 2. 61 54
19004499 2009
44
Autosomal-dominant cerulean cataract in a chinese family associated with gene conversion mutation in beta-B2-crystallin. 54 61
19321936 2009
45
Disulfide cross-links in the interaction of a cataract-linked alphaA-crystallin mutant with betaB1-crystallin. 61 54
19071118 2009
46
N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. 54 61
19503764 2009
47
Synergistic effect of osmotic and oxidative stress in slow-developing cataract formation. 54 61
18760274 2008
48
A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-carboxylate synthase (P5CS), causes an autosomal recessive neurocutaneous syndrome. 61 54
18478038 2008
49
Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. 54 61
18692043 2008
50
Mechanism of insolubilization by a single-point mutation in alphaA-crystallin linked with hereditary human cataracts. 54 61
18700785 2008

Variations for Cataract

ClinVar genetic disease variations for Cataract:

6 (show top 50) (show all 93)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu) SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
2 SIL1 NC_000005.10:g.139189727_139201554del Deletion Pathogenic 812923 5:138525416-138537243
3 SIL1 NC_000005.10:g.139189727_139201554del Deletion Pathogenic 812923 5:138525416-138537243
4 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg) SNV Pathogenic 523376 rs142285818 3:129251570-129251570 3:129532727-129532727
5 LIM2 NM_001161748.2(LIM2):c.388C>T (p.Arg130Cys) SNV Pathogenic 625113 rs1568480054 19:51883831-51883831 19:51380577-51380577
6 COL5A1 NM_001278074.1(COL5A1):c.608G>T (p.Gly203Val) SNV Likely pathogenic 523328 rs1554781700 9:137593133-137593133 9:134701287-134701287
7 WRN NM_000553.6(WRN):c.724+1G>T SNV Likely pathogenic 523380 rs1339616347 8:30925844-30925844 8:31068328-31068328
8 COL18A1 NM_030582.4(COL18A1):c.1469-2A>G SNV Likely pathogenic 373962 rs765919785 21:46897323-46897323 21:45477409-45477409
9 COL18A1 NM_030582.4(COL18A1):c.3979C>T (p.Arg1327Ter) SNV Likely pathogenic 373961 rs1057518802 21:46929468-46929468 21:45509554-45509554
10 PITX2 NM_153427.2(PITX2):c.-1092G>A SNV Uncertain significance 899797 4:111559018-111559018 4:110637862-110637862
11 PITX2 NM_153427.2(PITX2):c.-300A>T SNV Uncertain significance 900657 4:111558226-111558226 4:110637070-110637070
12 PITX2 NM_153427.2(PITX2):c.-483C>T SNV Uncertain significance 900734 4:111558409-111558409 4:110637253-110637253
13 PITX2 NM_153427.2(PITX2):c.-515C>T SNV Uncertain significance 899666 4:111558441-111558441 4:110637285-110637285
14 UPF3B NM_080632.2(UPF3B):c.758T>C (p.Ile253Thr) SNV Uncertain significance 284394 rs754982440 X:118975088-118975088 X:119841125-119841125
15 MMAA NM_172250.3(MMAA):c.304G>A (p.Ala102Thr) SNV Uncertain significance 523564 rs1328584680 4:146560595-146560595 4:145639443-145639443
16 PITX2 NM_153427.2(PITX2):c.-1421G>C SNV Uncertain significance 899913 4:111563111-111563111 4:110641955-110641955
17 PITX2 NM_153427.2(PITX2):c.-1422C>A SNV Uncertain significance 899914 4:111563112-111563112 4:110641956-110641956
18 PITX2 NM_000325.6(PITX2):c.*173G>A SNV Uncertain significance 900360 4:111539108-111539108 4:110617952-110617952
19 PITX2 NM_000325.6(PITX2):c.695G>A (p.Ser232Asn) SNV Uncertain significance 900415 4:111539561-111539561 4:110618405-110618405
20 PITX2 NM_000325.6(PITX2):c.282G>T (p.Arg94=) SNV Uncertain significance 900537 4:111542449-111542449 4:110621293-110621293
21 PITX2 NM_153427.2(PITX2):c.-670C>T SNV Uncertain significance 900813 4:111558596-111558596 4:110637440-110637440
22 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His) SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616
23 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu) SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937
24 TALDO1 NM_006755.2(TALDO1):c.328A>G (p.Arg110Gly) SNV Uncertain significance 523493 rs766745943 11:759056-759056 11:759056-759056
25 EPM2A NM_005670.4(EPM2A):c.*1691G>A SNV Uncertain significance 523391 rs750320097 6:145946861-145946861 6:145625725-145625725
26 PITX2 NM_000325.6(PITX2):c.*696A>C SNV Uncertain significance 901346 4:111538585-111538585 4:110617429-110617429
27 PITX2 NM_000325.6(PITX2):c.*687A>G SNV Uncertain significance 901347 4:111538594-111538594 4:110617438-110617438
28 PITX2 NM_000325.6(PITX2):c.*107A>C SNV Uncertain significance 901514 4:111539174-111539174 4:110618018-110618018
29 PITX2 NM_153427.2(PITX2):c.-1491G>A SNV Uncertain significance 901089 4:111563181-111563181 4:110642025-110642025
30 PITX2 NM_000325.6(PITX2):c.412-7C>T SNV Uncertain significance 899414 4:111539851-111539851 4:110618695-110618695
31 PITX2 NM_153427.2(PITX2):c.-40G>A SNV Uncertain significance 899457 4:111557966-111557966 4:110636810-110636810
32 PITX2 NM_153427.2(PITX2):c.-53G>A SNV Uncertain significance 899458 4:111557979-111557979 4:110636823-110636823
33 PITX2 NM_153427.2(PITX2):c.-270A>G SNV Uncertain significance 899520 4:111558196-111558196 4:110637040-110637040
34 PITX2 NM_153427.2(PITX2):c.-436G>C SNV Uncertain significance 899597 4:111558362-111558362 4:110637206-110637206
35 PITX2 NM_153427.2(PITX2):c.-501T>G SNV Uncertain significance 899665 4:111558427-111558427 4:110637271-110637271
36 PITX2 NM_153427.2(PITX2):c.-966A>G SNV Uncertain significance 899731 4:111558892-111558892 4:110637736-110637736
37 PITX2 NM_153427.2(PITX2):c.-1078C>A SNV Uncertain significance 899796 4:111559004-111559004 4:110637848-110637848
38 HSF4 NM_001040667.3(HSF4):c.*30del Deletion Uncertain significance 320192 rs756298250 16:67203717-67203717 16:67169814-67169814
39 PITX2 NM_000325.6(PITX2):c.*611A>G SNV Uncertain significance 347288 rs886059002 4:111538670-111538670 4:110617514-110617514
40 PITX2 NM_000325.6(PITX2):c.*370G>C SNV Uncertain significance 347293 rs886059005 4:111538911-111538911 4:110617755-110617755
41 PITX2 NM_000325.6(PITX2):c.*572T>C SNV Uncertain significance 347289 rs886059003 4:111538709-111538709 4:110617553-110617553
42 PITX2 NM_000325.6(PITX2):c.412-11del Deletion Uncertain significance 347299 rs886059007 4:111539855-111539855 4:110618699-110618699
43 CRYGD NM_006891.3(CRYGD):c.-80A>C SNV Uncertain significance 333880 rs886055528 2:208989277-208989277 2:208124553-208124553
44 PITX2 NM_000325.6(PITX2):c.*119T>A SNV Uncertain significance 347297 rs765040142 4:111539162-111539162 4:110618006-110618006
45 MIP NM_012064.4(MIP):c.*1237_*1238dup Duplication Uncertain significance 309864 rs111463603 12:56843825-56843826 12:56450041-56450042
46 MIP NM_012064.4(MIP):c.*148dup Duplication Uncertain significance 309881 rs35639464 12:56844915-56844916 12:56451131-56451132
47 MIP NM_012064.4(MIP):c.*1777dup Duplication Uncertain significance 309861 rs886049688 12:56843286-56843287 12:56449502-56449503
48 HSF4 NM_001538.3(HSF4):c.*158_*159dupTT Duplication Uncertain significance 320194 rs3215366 16:67203835-67203836 16:67169932-67169933
49 PITX2 NM_000325.6(PITX2):c.*176A>T SNV Uncertain significance 347296 rs567517676 4:111539105-111539105 4:110617949-110617949
50 PITX2 NM_000325.6(PITX2):c.*373_*375GTT[1] Microsatellite Uncertain significance 347292 rs886059004 4:111538903-111538905 4:110617747-110617749

Copy number variations for Cataract from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 86882 14 67000000 106368585 Copy number cataract
2 89231 15 17000000 100338915 Copy number cataract
3 106728 17 1 11200000 Copy number cataract

Expression for Cataract

Search GEO for disease gene expression data for Cataract.

Pathways for Cataract

Pathways related to Cataract according to KEGG:

36
# Name Kegg Source Accession
1 Protein processing in endoplasmic reticulum hsa04141

GO Terms for Cataract

Cellular components related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gap junction GO:0005921 8.96 GJA8 GJA3
2 connexin complex GO:0005922 8.62 GJA8 GJA3

Biological processes related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.43 RHO GJA3 CRYGS CRYGD CRYBA1 CRYAA
2 gap junction-mediated intercellular transport GO:1990349 9.16 GJA8 GJA3
3 lens development in camera-type eye GO:0002088 9.02 LIM2 GJA8 CRYGS CRYGD CRYBA1

Molecular functions related to Cataract according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of eye lens GO:0005212 9.02 LIM2 CRYGS CRYGD CRYBA1 CRYAA
2 gap junction channel activity GO:0005243 8.96 GJA8 GJA3

Sources for Cataract

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....